BACKGROUND Early puberty suppression (ePS; Tanner stages 2 and 3) through gonadotropin-releasing hormone agonists (GnRHas) and gender-affirming hormones (GAHs) interferes with growth and may impact final height (FH). AIM To investigate the impact of ePS and GAH on FH in trans boys and trans girls. METHODS Retrospective study, including 10 trans boys and 22 trans girls at FH. Bone age (BA) was determined at the start of ePS and at the start of GAH according to Greulich and Pyle; predicted adult height (PAH) was calculated according to Bayley and Pinneau's tables; target height (TH) was calculated as adjusted mean of maternal and paternal height. Target height, PAH, and BA were determined according to sex registered at birth (SRAB) and experienced gender (EG). RESULTS The age at the start of PS was 12.37 ± 0.74 years in trans boys and 13.10 ± 1.12 years in trans girls. Total height gain since the start of ePS in trans boys was 14.62 ± 4.08 cm, with 70% achieved before the start of GAH. In trans girls, it was 20.68 ± 7.66 cm, with 61% achieved before GAH. Target height for SRAB was the most accurate predictor for FH in both trans boys and girls: the difference with FH was 1.57 cm ± 3.1 (P = .168) and -0.98 cm ± 4.17 (P = .319), respectively. Also the difference between FH and PAH at the start of PS for SRAB was nonsignificant in both trans boys and girls (2.62 cm ± 3.79, P = .056 and -2.35 cm ± 5.2, P = .051, respectively). CONCLUSION Early puberty suppression and GAH do not impact FH, supporting the safety of the treatment; however, trans adolescents achieve a FH in line with SRAB, rather than EG.

中文翻译：

---

青春期早期抑制和性别肯定激素不会改变跨性别青少年的最终身高。

背景 通过促性腺激素释放激素激动剂 (GnRHas) 和性别确认激素 (GAH) 抑制青春期早期（ePS；Tanner 2 期和 3 期）会干扰生长，并可能影响最终身高 (FH)。目的 探讨 ePS 和 GAH 对跨性别男孩和跨性别女孩 FH 的影响。方法 回顾性研究，包括 FH 的 10 名跨性别男孩和 22 名跨性别女孩。根据 Greulich 和 Pyle 的方法，在 ePS 开始时和 GAH 开始时测定骨龄 (BA)；根据 Bayley 和 Pinneau 的表格计算预测成年身高 (PAH)；目标身高 (TH) 计算为母亲和父亲身高的调整平均值。目标身高、PAH 和 BA 根据出生登记性别 (SRAB) 和经历性别 (EG) 确定。结果 跨性别男孩开始 PS 的年龄为 12.37 ± 0.74 岁，跨性别女孩为 13.10 ± 1.12 岁。自 ePS 开始以来，跨性别男孩的总身高增长为 14.62 ± 4.08 厘米，其中 70% 在 GAH 开始前达到。跨性别女孩的身高为 20.68 ± 7.66 厘米，其中 61% 在 GAH 之前达到。SRAB 的目标身高是跨性别男孩和女孩中 FH 最准确的预测因子：与 FH 的差异分别为 1.57 cm ± 3.1 (P = .168) 和 -0.98 cm ± 4.17 (P = .319)。此外，在 SRAB 的 PS 开始时，FH 和 PAH 之间的差异在跨性别男孩和女孩中均不显着（分别为 2.62 cm ± 3.79，P = 0.056 和 -2.35 cm ± 5.2，P = 0.051）。结论 青春期早期抑制和 GAH 不会影响 FH，支持治疗的安全性；然而，跨性别青少年根据 SRAB 而不是 EG 获得 FH。